Skip to Main Content

Paper Details

Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines.
Pharmacological Reviews
7
2022
Omicron, SARS, SARS-, SARS-CoV, SARS-CoV-2, SARS-CoV-2 virus, Severe, Severe Acute Respiratory Syndrome Coronavirus, human, severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus
Author NameAffiliation
Rino RappuoliR.R.) Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard University, California (Y.K.) and La Jolla Institute for Immunology
  • 1 - 1

Datasets

Release 1.2